Home » USA Broker Ratings » Alnylam Pharmaceuticals – Consenus Indicates Potential 31.9% Upside

Alnylam Pharmaceuticals – Consenus Indicates Potential 31.9% Upside

Alnylam Pharmaceuticals with ticker code (ALNY) have now 20 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 200 and 75 with a mean TP of 141.45. Given that the stocks previous close was at 107.21 this now indicates there is a potential upside of 31.9%. There is a 50 day moving average of 114.09 and the 200 moving average now moves to 105.04. The company has a market cap of $11,782m. Find out more information at: http://www.alnylam.com

Alnylam Pharmaceuticals, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals; and Regeneron Pharmaceuticals, as well as collaboration with Vir Biotechnology to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Join us on our new LinkedIn page

Follow us on LinkedIn